BNN Bloomberg
🏢 Bell Media
May 26, 2026
· 2 min read
Quick Score
○ Unverifiable
View full audit trail →
Lilly to buy three vaccine developers for nearly US$4 billion in infectious disease push - BNN Bloomberg
Original article ↗B.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
0.281 · RIGHT
Ensemble
0.141 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.030
3,171 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
Eli Lilly said on Tuesday it will buy three vaccine developers in deals worth up to US$3.8 billion in combined value, signaling its push into infectious disease prevention.
The U.S. drugmaker said it had agreed to acquire Curevo, LimmaTech Biologics and Vaccine Company.
Lilly has been on an acquisition spree, boosted by cash from the booming demand for its obesity drugs. Its deal spending in 2026 has outpaced that in the prior years.
The deals mark Lilly’s renewed move into the infectious disease space, which was largely sidelined in recent years as the company focused on expanding its othe…
Read full article at BNN Bloomberg ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.